Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | ALDH1A3 | P47895 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431737 | 0.86 | NR4A2 (0.75) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3433254 | 0.85 | NR4A2 (0.74) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3432051 | 0.84 | NR4A2 (0.72) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3432413 | 0.83 | NR4A2 (0.71) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3429522 | 0.82 | NR4A2 (0.69) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3429756 | 0.81 | NR4A2 (0.69) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3430915 | 0.81 | NR4A2 (0.68) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3429517 | 0.81 | NR4A2 (0.68) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3431035 | 0.81 | NR4A2 (0.68) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3432610 | 0.81 | NR4A2 (0.67) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024100285-A1 | TREATMENT OF A COGNITIVE DISORDER WITH AN AGENT THAT INCREASES THE EXCITABILITY OF THE CLAUSTRUM | UNIVERSITÉ DE GENÈVE (CH) | 2024-05-16 | — | — | WO | claimed |
| US-7915284-B2 | 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | claimed |
| EP-2069342-B1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-05-12 | — | — | EP | claimed |
| US-20090253735-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | claimed |
| WO-2024100285-A1 | TREATMENT OF A COGNITIVE DISORDER WITH AN AGENT THAT INCREASES THE EXCITABILITY OF THE CLAUSTRUM | UNIVERSITÉ DE GENÈVE (CH) | 2024-05-16 | — | — | WO | disclosed |
| EP-2262769-B1 | POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-7915284-B2 | 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | disclosed |
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| EP-2069342-B1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-05-12 | — | — | EP | disclosed |
| US-20090253735-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| EP-2069342-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-ALPHA]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008034974-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-α]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253735-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NCOR1, NR4A2, NR4A3 | NR4A2 2/4885KCNH2 2584/4885CYP2C9 2993/4885 |
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | JAK2, ABL1, REN | NR4A2 1394/4885KCNH2 1641/4885CYP2C9 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.